StreetInsider.com News Articles

Mizuho on Axsome Therapeutics (AXSM): 'recommend buying ahead of AXSM's 3Q print'

Wed, 21 Oct 2026 05:26:38 -0400

Mizuho analyst Graig Suvannavejh reiterated an Outperform rating and $316.00 price target on Axsome Therapeutics (NASDAQ: AXSM).

The analyst comments "Ahead of AXSM's 3Q26 earnings on 11/2, we provide a quarterly preview, and further, revisit the Auvelity launch in Alzheimer's disease agitation/ADA (the #1 focus for investors). For 3Q, we adjust our total revenue estimate to $251.5mn — 2% lower than our prior $257.4mn, but still slightly ahead of consensus of $251.0mn — while for Auvelity (the only one amongst AXSM's three marketed products that really matters to investors), our revenue forecast moves to $208.9mn (vs. $213.1mn prior). On the ADA

RBC Capital Defending Axsome Therapeutics (AXSM): 'we would be buyers at these levels'

Wed, 14 Oct 2026 05:58:22 -0400

RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $295.00 price target on Axsome Therapeutics (NASDAQ: AXSM).

The analyst comments "Given recent weakness in the last month (shares down ~28% vs. XBI down ~6%) driven by lower than expected Rx trends, and AXSM now trading ~15% lower than before approval in AD agitation, we think the stock is fundamentally dislocated from fair value, and there could be upside from 3Q26 earnings. Although we acknowledge concerns that the trajectory of early launch could have readthrough into the peak opportunity, we believe recent Rx trends are the result of seasonal effects and

Axsome Therapeutics (AXSM) PT Lowered to $295 at RBC Capital

Thu, 08 Oct 2026 08:27:02 -0400

RBC Capital analyst Leonid Timashev lowered the price target on Axsome Therapeutics (NASDAQ: AXSM) to $295.00 (from $297.00) while maintaining a Outperform rating.

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

Wed, 07 Oct 2026 07:00:00 -0400

NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the third quarter of 2026 on Monday, November 2, 2026, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business update.

To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851

Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2

Wed, 07 Oct 2026 07:00:00 -0400

To participate in the live conference call, please dial (877) 405-1239 (toll-free domestic) or +1 (201) 389-0851

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

3 high-conviction SMID-cap biotech stocks to buy: Jefferies

Thu, 01 Oct 2026 15:00:00 -0400

Jefferies named the stocks it sees as high-conviction small- and mid-cap biotech ideas in a new note to clients.

The stocks in question are Definium Therapeutics (NASDAQ: DFTX), Axsome Therapeutics (NASDAQ: AXSM), and BridgeBio Pharma (NASDAQ: BBIO).

Analyst Andrew Tsai said a tougher macro backdrop, including rising interest rates, is pressuring the SMID-cap space.

That has him wondering whether investor appetite may shift back toward late-stage and commercial names rather than binary catalysts.

The firm noted that its picks are a “cheap stocks that look de-risked and have strong peak sales and meaningful upside potential.”

On Definium Therapeutics, Tsai pointed to three positive Phase

Wells Fargo names 13 stocks as overweight tactical ideas